Literature DB >> 24422674

Corallorazines from the myxobacterium Corallococcus coralloides.

Alexander Schmitz1, Stefan Kehraus, Till F Schäberle, Edith Neu, Celso Almeida, Martin Roth, Gabriele M König.   

Abstract

The myxobacterium Corallococcus coralloides is the producer of the antibiotic compound corallopyronin A, which is currently in preclinical evaluation. To obtain suitable amounts of this antibiotic, the production strain C. coralloides B035 was cultured in large volumes, which in the addition to the isolation of the target molecule facilitates the detection of additional metabolites of this myxobacterial strain (corallorazines A-C). Corallorazine A is a new structural type of dipeptide composed of a dehydroalanine and a glycine moiety that are linked via a semiaminal bond, thus forming a piperazine ring. The latter is further connected via an amide bond to an unusual aliphatic acyl chain.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24422674     DOI: 10.1021/np400740u

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  3 in total

1.  Corallococcus soli sp. Nov., a Soil Myxobacterium Isolated from Subtropical Climate, Chalus County, Iran, and Its Potential to Produce Secondary Metabolites.

Authors:  Zahra Khosravi Babadi; Ronald Garcia; Gholam Hossein Ebrahimipour; Chandra Risdian; Peter Kämpfer; Michael Jarek; Rolf Müller; Joachim Wink
Journal:  Microorganisms       Date:  2022-06-21

2.  Myxobacteria Are Able to Prey Broadly upon Clinically-Relevant Pathogens, Exhibiting a Prey Range Which Cannot Be Explained by Phylogeny.

Authors:  Paul G Livingstone; Russell M Morphew; David E Whitworth
Journal:  Front Microbiol       Date:  2017-08-22       Impact factor: 5.640

3.  In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin A.

Authors:  Tim Becker; Anna K Krome; Sahel Vahdati; Andrea Schiefer; Kenneth Pfarr; Alexandra Ehrens; Tilman Aden; Miriam Grosse; Rolf Jansen; Silke Alt; Thomas Hesterkamp; Marc Stadler; Marc P Hübner; Stefan Kehraus; Gabriele M König; Achim Hoerauf; Karl G Wagner
Journal:  Pharmaceutics       Date:  2022-08-09       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.